Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Anastrozole + Zenocutuzumab |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Anastrozole | Arimidex | Anastrozol | Aromatase Inhibitor 3 | Arimidex (anastrozole) is an aromatase inhibitor, which inhibits estrogen synthesis (PMID: 29719441). Arimidex (anastrozole) is FDA approved for postmenopausal women with hormone receptor-positive early breast cancer or advanced patients who have failed tamoxifen therapy (FDA.gov). |
Zenocutuzumab | MCLA-128|MCLA128|MCLA 128 | HER2 (ERBB2) Antibody 76 HER3 (ERBB3) Antibody 23 | Zenocutuzumab (MCLA-128) is a bispecific antibody that targets Erbb2 (Her2) and Erbb3, resulting in antibody-dependent cell-mediated cytotoxicity against tumor cells (Cancer Res 2016;76(14 Suppl):Abstract nr CT050, PMID: 32054397). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03321981 | Phase II | Letrozole + Zenocutuzumab Anastrozole + Zenocutuzumab Fulvestrant + Zenocutuzumab Exemestane + Zenocutuzumab Trastuzumab + Zenocutuzumab Trastuzumab + Vinorelbine + Zenocutuzumab | MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer | Completed | USA | NLD | GBR | FRA | ESP | BEL | 1 |